Fate Therapeutics Announces Publication of Its Proprietary Stem Cell...

The publication describes the use of the Company's hiPSC platform, consisting of stage-specific cell culture systems, to enable rapid, parallel derivation of hiPSC clones and their subsequent expansion as transgene-free, single cells in culture.

http://ift.tt/1g2BVkS